000275934 001__ 275934
000275934 005__ 20240229154948.0
000275934 0247_ $$2doi$$a10.1016/j.radonc.2023.109678
000275934 0247_ $$2pmid$$apmid:37146766
000275934 0247_ $$2ISSN$$a0167-8140
000275934 0247_ $$2ISSN$$a1879-0887
000275934 0247_ $$2altmetric$$aaltmetric:147896664
000275934 037__ $$aDKFZ-2023-00922
000275934 041__ $$aEnglish
000275934 082__ $$a610
000275934 1001_ $$aScharl, Sophia$$b0
000275934 245__ $$aSalvage radiotherapy is effective in patients with PSMA-PET-negative biochemical recurrence- results of a retrospective study.
000275934 260__ $$aAmsterdam [u.a.]$$bElsevier Science$$c2023
000275934 3367_ $$2DRIVER$$aarticle
000275934 3367_ $$2DataCite$$aOutput Types/Journal article
000275934 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1687355745_6281
000275934 3367_ $$2BibTeX$$aARTICLE
000275934 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000275934 3367_ $$00$$2EndNote$$aJournal Article
000275934 500__ $$a2023 Jul;184:109678
000275934 520__ $$a/Purpose: The present study aimed to assess whether SRT to the prostatic fossa should be initiated in a timely manner after detecting biochemical recurrence (BR) in patients with prostate cancer, when no correlate was identified with prostate-specific membrane antigen positron emission tomography (PSMA-PET).This retrospective, multicenter analysis included 1222 patients referred for PSMA-PET after a radical prostatectomy due to BR. Exclusion criteria were: pathological lymph node metastases, prostate-specific antigen (PSA) persistence, distant or lymph node metastases, nodal irradiation, and androgen deprivation therapy (ADT). This led to a cohort of 341 patients. Biochemical progression-free survival (BPFS) was the primary study endpoint.The median follow-up was 28.0 months. The 3-year BPFS was 71.6% in PET-negative cases and 80.8% in locally PET-positive cases. This difference was significant in univariate (p=0.019), but not multivariate analyses (p=0.366, HR: 1.46, 95%CI: 0.64-3.32). The 3-year BPFS in PET-negative cases was significantly influenced by age (p=0.005), initial pT3/4 (p<0.001), pathology scores (ISUP) ≥3 (p=0.026), and doses to fossa >70 Gy (p=0.027) in univariate analyses. In multivariate analyses, only age (HR: 1.096, 95%CI: 1.023-1.175, p=0.009) and PSA-doubling time (HR: 0.339, 95%CI: 0.139-0.826, p=0.017) remained significant.To our best knowledge, this study provided the largest SRT analysis in patients without ADT that were lymph node-negative on PSMA-PET. A multivariate analysis showed no significant difference in BPFS between locally PET-positive and PET-negative cases. These results supported the current EAU recommendation to initiate SRT in a timely manner after detecting BR in PET negative patients.
000275934 536__ $$0G:(DE-HGF)POF4-315$$a315 - Bildgebung und Radioonkologie (POF4-315)$$cPOF4-315$$fPOF IV$$x0
000275934 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000275934 650_7 $$2Other$$aPET negative
000275934 650_7 $$2Other$$aPSMA PET-CT
000275934 650_7 $$2Other$$aprostate cancer
000275934 650_7 $$2Other$$asalvage radiotherapy
000275934 7001_ $$0P:(DE-HGF)0$$aZamboglou, Constantinos$$b1
000275934 7001_ $$aStrouthos, Iosif$$b2
000275934 7001_ $$aFarolfi, Andrea$$b3
000275934 7001_ $$aSerani, Francesca$$b4
000275934 7001_ $$aLanzafame, Helena$$b5
000275934 7001_ $$aGiuseppe Morganti, Alessio$$b6
000275934 7001_ $$aTrapp, Christian$$b7
000275934 7001_ $$0P:(DE-HGF)0$$aKoerber, Stefan A$$b8
000275934 7001_ $$0P:(DE-He78)8714da4e45acfa36ce87c291443a9218$$aDebus, Jürgen$$b9$$udkfz
000275934 7001_ $$0P:(DE-HGF)0$$aPeeken, Jan C$$b10
000275934 7001_ $$0P:(DE-HGF)0$$aVogel, Marco M E$$b11
000275934 7001_ $$aVrachimis, Alexis$$b12
000275934 7001_ $$0P:(DE-HGF)0$$aK B Spohn, Simon$$b13
000275934 7001_ $$0P:(DE-HGF)0$$aRuf, Juri$$b14
000275934 7001_ $$0P:(DE-HGF)0$$aGrosu, Anca-Ligia$$b15
000275934 7001_ $$aCeci, Francesco$$b16
000275934 7001_ $$aFendler, Wolfgang P$$b17
000275934 7001_ $$aBartenstein, Peter$$b18
000275934 7001_ $$aKroeze, Stephanie G C$$b19
000275934 7001_ $$aGuckenberger, Matthias$$b20
000275934 7001_ $$aKrafcsik, Manuel$$b21
000275934 7001_ $$aKlopscheck, Christina$$b22
000275934 7001_ $$aFanti, Stefano$$b23
000275934 7001_ $$aHruby, George$$b24
000275934 7001_ $$aEmmett, Louise$$b25
000275934 7001_ $$aBelka, Claus$$b26
000275934 7001_ $$aStief, Christian$$b27
000275934 7001_ $$aSchmidt-Hegemann, Nina-Sophie$$b28
000275934 7001_ $$aHenkenberens, Christoph$$b29
000275934 7001_ $$aMayer, Benjamin$$b30
000275934 7001_ $$aMiksch, Jonathan$$b31
000275934 7001_ $$aShelan, Mohamed$$b32
000275934 7001_ $$aAebersold, Daniel M$$b33
000275934 7001_ $$aThamm, Reinhard$$b34
000275934 7001_ $$aWiegel, Thomas$$b35
000275934 773__ $$0PERI:(DE-600)1500707-8$$a10.1016/j.radonc.2023.109678$$gp. 109678 -$$p109678$$tRadiotherapy and oncology$$v184$$x0167-8140$$y2023
000275934 909CO $$ooai:inrepo02.dkfz.de:275934$$pVDB
000275934 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000275934 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b8$$kDKFZ
000275934 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)8714da4e45acfa36ce87c291443a9218$$aDeutsches Krebsforschungszentrum$$b9$$kDKFZ
000275934 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b10$$kDKFZ
000275934 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b11$$kDKFZ
000275934 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b13$$kDKFZ
000275934 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b14$$kDKFZ
000275934 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b15$$kDKFZ
000275934 9131_ $$0G:(DE-HGF)POF4-315$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vBildgebung und Radioonkologie$$x0
000275934 9141_ $$y2023
000275934 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2022-11-29
000275934 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2022-11-29
000275934 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2022-11-29
000275934 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2023-10-21$$wger
000275934 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bRADIOTHER ONCOL : 2022$$d2023-10-21
000275934 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-21
000275934 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-21
000275934 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2023-10-21
000275934 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2023-10-21
000275934 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-21
000275934 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-10-21
000275934 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-21
000275934 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2023-10-21
000275934 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bRADIOTHER ONCOL : 2022$$d2023-10-21
000275934 9201_ $$0I:(DE-He78)FR01-20160331$$kFR01$$lDKTK Koordinierungsstelle Freiburg$$x0
000275934 9201_ $$0I:(DE-He78)E050-20160331$$kE050$$lE050 KKE Strahlentherapie$$x1
000275934 9201_ $$0I:(DE-He78)MU01-20160331$$kMU01$$lDKTK Koordinierungsstelle München$$x2
000275934 980__ $$ajournal
000275934 980__ $$aVDB
000275934 980__ $$aI:(DE-He78)FR01-20160331
000275934 980__ $$aI:(DE-He78)E050-20160331
000275934 980__ $$aI:(DE-He78)MU01-20160331
000275934 980__ $$aUNRESTRICTED